淋巴瘤化疗后粒细胞减少预防中聚乙二醇化重组人粒细胞集落刺激因子的应用观察(1)
【摘要】 目的：探討聚乙二醇化重组人粒细胞集落刺激因子对淋巴瘤化疗后粒细胞减少的预防作用。方法：选取60例淋巴瘤化疗患者进行分析，将其随机分组，观察组给予聚乙二醇化重组人粒细胞集落刺激因子，对照组给予重组人粒细胞集落刺激因子，每组各30例。结果：治疗后，两组患者的生存质量计分、KPS评分均显著优于治疗前(P<0.05)，且观察组显著优于对照组(P<0.05)。观察组平均最低ANC值为(5.31±0.51)×109/L，ANC<2.0×109/L持续时间为(3.15±1.02)d，对照组平均最低ANC值为(5.52±0.48)×109/L，ANC<2.0×109/L持续时间为(4.01±1.13)d，两组比较差异均无统计学意义(P>0.05)。观察组患者的不良反应发生率为13.33%，对照组患者的不良反应发生率为6.67%，两组比较差异无统计学意义(P>0.05)。结论：聚乙二醇化重组人粒细胞集落刺激因子一次给药在预防淋巴瘤化疗后粒细胞减少方面的效果与重组人粒细胞集落刺激因子多次给药比较更优，故更值得推广前一种方案。
【关键词】 聚乙二醇化重组人粒细胞集落刺激因子； 淋巴瘤； 粒细胞； 重组人粒细胞集落刺激因子
, 百拇医药
Application of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor in Prophylaxis of Granulocytosis after Chemotherapy of Lymphoma/YAO Da’na，WU Fuqun.//Medical Innovation of China，2018，15(13)：031-034
【Abstract】 Objective：To investigate the preventive effect of recombinant human granulocyte colony-stimulating factor (pegf) on granulocytosis after chemotherapy of lymphoma.Method：54 cases of lymphoma chemotherapy patients were analyzed. They were randomly divided into two groups.The observation group was treated with pegylated recombinant human granulocyte colony-stimulating factor，and the control group was treated with recombinant human granulocyte colony-stimulating factor，30 cases in each group.Result：After treatment，the scores of quality of life and KPS in the observation group and the control group were significantly better than those before treatment(P<0.05).After treatment，the quality of life score and KPS score in the observation group were significantly better than those in the control group(P<0.05).The observation group of average minimum ANC value was (5.31±0.51)×109/L，ANC<2×109/L duration was (3.15±1.02)d，the average minimum ANC value in control group was (5.52±0.48)×109/L，ANC<2×109/L duration was(4.01±1.13)d，two groups were no significant difference in statistical significance(P>0.05).The incidence of adverse reactions in the observation group was 13.33%， and the incidence of adverse reactions in the control group was 6.67%，there was no significant difference between the two groups (P>0.05).Conclusion：Pegylated recombinant human granulocyte colony-stimulating factor is better than single recombinant human granulocyte colony-stimulating factor in preventing neutrophils after chemotherapy for lymphatic cancer，so it is worthy of promoting the former one.
【Key words】 Pegylated recombinant human granulocyte colony stimulating factor； Lymphoma； Granulocyte； Recombinant human granulocyte colony-stimulating factor, 百拇医药(姚达娜 吴福群)
【关键词】 聚乙二醇化重组人粒细胞集落刺激因子； 淋巴瘤； 粒细胞； 重组人粒细胞集落刺激因子
, 百拇医药
Application of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor in Prophylaxis of Granulocytosis after Chemotherapy of Lymphoma/YAO Da’na，WU Fuqun.//Medical Innovation of China，2018，15(13)：031-034
【Abstract】 Objective：To investigate the preventive effect of recombinant human granulocyte colony-stimulating factor (pegf) on granulocytosis after chemotherapy of lymphoma.Method：54 cases of lymphoma chemotherapy patients were analyzed. They were randomly divided into two groups.The observation group was treated with pegylated recombinant human granulocyte colony-stimulating factor，and the control group was treated with recombinant human granulocyte colony-stimulating factor，30 cases in each group.Result：After treatment，the scores of quality of life and KPS in the observation group and the control group were significantly better than those before treatment(P<0.05).After treatment，the quality of life score and KPS score in the observation group were significantly better than those in the control group(P<0.05).The observation group of average minimum ANC value was (5.31±0.51)×109/L，ANC<2×109/L duration was (3.15±1.02)d，the average minimum ANC value in control group was (5.52±0.48)×109/L，ANC<2×109/L duration was(4.01±1.13)d，two groups were no significant difference in statistical significance(P>0.05).The incidence of adverse reactions in the observation group was 13.33%， and the incidence of adverse reactions in the control group was 6.67%，there was no significant difference between the two groups (P>0.05).Conclusion：Pegylated recombinant human granulocyte colony-stimulating factor is better than single recombinant human granulocyte colony-stimulating factor in preventing neutrophils after chemotherapy for lymphatic cancer，so it is worthy of promoting the former one.
【Key words】 Pegylated recombinant human granulocyte colony stimulating factor； Lymphoma； Granulocyte； Recombinant human granulocyte colony-stimulating factor, 百拇医药(姚达娜 吴福群)
参见：首页 > 医疗版 > 疾病专题 > 血液内科 > 淋巴瘤